A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Laboratory values meeting the protocol's criteria within the screening period (-28 days) prior to the first dose of study drug.
Participants with a diagnosis of a malignant solid tumor by histology (World Health Organization \[WHO\] criteria).
Participants with measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
You may not be if
Unresolved Grade \> 1 adverse events (AEs) from prior anti-cancer therapy except for alopecia.
Active systemic or uncontrolled local bacterial, fungal, or viral infection requiring antimicrobial therapy.
History of hypersensitivity to the active ingredients or any excipients of ABBV-303 and budigalimab (ABBV-181).
Body weight \< 35 kg.
Clareo Health | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
